Success Metrics

Clinical Success Rate
85.7%

Based on 36 completed trials

Completion Rate
86%(36/42)
Active Trials
10(14%)
Results Posted
33%(12 trials)
Terminated
6(8%)

Phase Distribution

Ph not_applicable
21
29%
Ph phase_4
1
1%
Ph phase_2
7
10%
Ph phase_3
1
1%
Ph phase_1
9
13%

Phase Distribution

9

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution39 total trials
Phase 1Safety & dosage
9(23.1%)
Phase 2Efficacy & side effects
7(17.9%)
Phase 3Large-scale testing
1(2.6%)
Phase 4Post-market surveillance
1(2.6%)
N/ANon-phased studies
21(53.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

36 of 45 finished

Non-Completion Rate

20.0%

9 ended early

Currently Active

10

trials recruiting

Total Trials

72

all time

Status Distribution
Active(12)
Completed(36)
Terminated(9)
Other(15)

Detailed Status

Completed36
unknown15
Recruiting8
Terminated6
Withdrawn3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
72
Active
10
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 19 (23.1%)
Phase 27 (17.9%)
Phase 31 (2.6%)
Phase 41 (2.6%)
N/A21 (53.8%)

Trials by Status

withdrawn34%
completed3650%
active_not_recruiting23%
terminated68%
recruiting811%
unknown1521%
not_yet_recruiting23%

Recent Activity

Clinical Trials (72)

Showing 20 of 72 trialsScroll for more
NCT06292377Not Applicable

Better Understanding of Fatigue After STroke

Recruiting
NCT05286827Phase 2

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Terminated
NCT02780128Phase 1

Next Generation Personalized Neuroblastoma Therapy

Terminated
NCT07460154Not Applicable

Structured Review: To Optimise Management and Prevent Harm in COPD

Not Yet Recruiting
NCT05573633Not Applicable

Diagnosis of Postoperative Atrial Fibrillation by a Smartwatch

Recruiting
NCT04316650Not Applicable

Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia

Withdrawn
NCT04294641Phase 2

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed
NCT07364656Not Applicable

Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors

Not Yet Recruiting
NCT04167033Not Applicable

Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)

Recruiting
NCT05918055Phase 1

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Terminated
NCT04896073Phase 2

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Completed
NCT05148234Phase 1

BMS-986253 in Myelodysplastic Syndromes

Terminated
NCT02356159Phase 1

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Completed
NCT03070496Not Applicable

Multicenter Cohort of STEMI Patients

Completed
NCT02769962Phase 1

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Completed
NCT07078071Not Applicable

Clinical Trial for Evaluating the Effectiveness and Safety of the Pulse Wave-based Atrial Fibrillation and Premature Beat Alert Software

Completed
NCT06724718Not Applicable

Diagnosis of Atrial Fibrillation in Postoperative Thoracic Surgery Using a Smartwatch

Recruiting
NCT04115553Not Applicable

Assessment of Venous Drainage in Idiopathic Intracranial Hypertension

Active Not Recruiting
NCT03448393Phase 1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Completed
NCT03898596Not Applicable

Umbilical Vessel Catheterization Under ECG Monitoring and Guidance

Recruiting

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
72